Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Wize Pharma logo — Wize Pharma, Inc. is a clinical-stage biopharmaceutical comp...

Wize Pharma

Wize Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders.

Founded 1982 Israel Israel 2 employees Post-IPO Equity Total: $7.50M Biopharma, Biotechnology +2

General Information

Company Name Wize Pharma
Founded Year 1982
Location Israel Israel
Employees 2
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Wize Pharma . To contact Wize Pharma , visit wizepharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Wize Pharma compare?

A PDF of Wize Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Wize Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Wize Pharma

Wize Pharma is a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders. The company has in-licensed certain rights to purchase, market, sell, and distribute a formula known as LO2A, which is currently registered and marketed in Germany, Switzerland, Hungary, and the Netherlands for the treatment of Dry Eye Syndrome (DES), CCh, and Sjögren's syndrome (Sjögren's). Founded in 1982, Wize is based in Israel and recently received a $7.50M Post-IPO Equity investment on 19 February 2020. The company has completed a Phase II trial of LO2A for patients with CCh and is currently conducting a Phase IV study for LO2A for DES in patients with Sjögren's. Wize's strategy involves engaging local or multinational distributors to handle the distribution of LO2A. As a promising player in the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries, Wize Pharma presents an exciting investment opportunity with its innovative approach to addressing ophthalmic disorders.

Business keywords: biopharmaceutical, ophthalmic disorders, clinical-stage, LO2A, drug development, distribution strategy, Phase II trial, Phase IV study, Sjögren's syndrome, CCh, in-licensing, pharmaceutical company, Israel, HaMerkaz

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $7.50M -
19 Feb 2020

Wize Pharma Alternatives & Competitors

View All Alternatives
Wize Pharma vs
Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc. United States

A clinical-stage biopharmaceutical company focused on central nervous system disorders and rare dise...

Post-IPO Equity
8 employees
Biotechnology, Pharmaceutical
Wize Pharma vs
Soligenix, Inc.
Soligenix, Inc. United States

We are a late-stage biopharmaceutical company focused on developing & commercializing products to tr...

Post-IPO Equity
27 employees
Biopharma, Biotechnology
Wize Pharma vs
Inventiva Pharma
Inventiva Pharma France

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapi...

Post-IPO Equity
108 employees
Biopharma, Biotechnology
Also compare with: Wize Pharma vs Prilenia Prilenia View all alternatives

FAQ About Wize Pharma

Wize Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders.
Wize Pharma was founded in 1982.
Wize Pharma is headquartered in Israel.
Wize Pharma operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical, ophthalmic disorders, clinical-stage and LO2A.
Wize Pharma has approximately 2 employees.
Wize Pharma has completed 1 funding round, raising a total of $7.50M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Wize Pharma include Seelos Therapeutics, Inc., Soligenix, Inc., Inventiva Pharma, Nuvamid, X4 Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Wize Pharma and Seelos Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Wize Pharma , https://bouncewatch.com/company/wize-pharma, updated 27 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes